Stock Taper
SCREENER COMPARE ANY 2 STOCKS
PCVX
VAXCYTE, INC.
NASDAQ
$59.84
▼ DOWN 2.16% (-1.32)

KEY STATISTICS

Market Cap$8.64 B
52w High$65.00
52w Low$30.81
Dividend Yield—
Frequency—
P/E-7.84
Volume759.73K
Shares Out.144.40M

COMPANY

LEADERSHIP

Grant E. Pickering
CHIEF EXECUTIVE
Grant E. Pickering

ABOUT

SECTOR
Healthcare
WENT PUBLIC
June 12, 2020
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
507

PRICE TARGET

Target High$163.00
Target Low$58.00
Target Median$89.00
Target Consensus$105.57

UPCOMING EARNINGS

DateNov 3, 2026
DayTuesday
Rev. Est.$12.50M
NOV
3
TUE

PRICE

$59.84 ▼ DOWN 2.16% (−$1.32)
$60.00$60.759:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM59.84

About Vaxcyte, Inc.

https://vaxcyte.com ↗

Vaxcyte, Inc. is a clinical-stage biotech company developing novel protein vaccines, including VAX-24 for pneumococcal disease, targeting bacterial infections and antibiotic resistance.

INDUSTRY

Biotechnology

A PRODUCT VAXCYTE, INC. IS KNOWN FOR

VAX-31
VAX-31

VAX-31 is a 31-valent pneumococcal conjugate vaccine in late-stage trials for adults and mid-stage for infants, designed to protect against 31 Streptococcus pneumoniae serotypes causing IPD, pneumonia, and otitis media.

COMPETITORS

COMPETITOR
GSK COMPARE
MRK COMPARE
PFE COMPARE
SNY COMPARE

Revenue by Products

IconPRODUCTQ3-2021Q4-2021Q1-2022Q2-2022
Pneumococcal Conjugate Vaccine$7B $0 ▼$7B ▲$7B

ETFS HOLDING THIS STOCK

ETFS HOLDING
183
LISTED HERE
26
RANKED BY POSITION SIZE
VTS.AX
0.01% · 4.6M
XSU.TO
0.25% · 3.4M
XBI
1.20% · 2.3M
TCAF
0.71% · 978.2K
SCHA
0.17% · 625.0K
DFAS
0.13% · 324.2K
FESM
0.12% · 131.6K
XRS2.DE
0.25% · 120.3K
LABU
0.81% · 84.7K
PRFZ
0.17% · 80.8K
JHMM
0.07% · 66.9K
RSSL
0.25% · 62.9K
BBMC
0.17% · 58.4K
BKMC
0.21% · 23.5K
AVUS
0.01% · 21.2K
IQSM
0.31% · 17.9K
MEDI
2.19% · 15.7K
GSSC
0.08% · 13.9K
SILX
3.70% · 13.7K
RTWO.L
0.35% · 12.8K
W311.DE
3.11% · 7.8K
TILT
0.02% · 7.4K
BBC
0.77% · 6.6K
GERM
4.52% · 5.4K
URTY
0.10% · 5.4K
STXK
0.37% · 5.3K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
84.26%
HOLDERS
451
TOP 12 OF 451 · RANKED BY POSITION SIZE
Fmr LLC
20.9M sh · $1.21B
Janus Henderson Group Plc
16.6M sh · $960.23M
Vanguard Group Inc
12.3M sh · $443.78M
T. Rowe Price Investment Management, Inc.
12.2M sh · $709.62M
Blackrock, Inc.
12.1M sh · $701.52M
Ra Capital Management, L.P.
12.0M sh · $431.01M
Blackrock Inc.
9.9M sh · $750.56M
Wellington Management Group Llp
7.0M sh · $407M
State Street Corp
5.4M sh · $311.09M
Paradigm Biocapital Advisors LP
4.8M sh · $278.52M
Deep Track Capital, LP
4.3M sh · $249.96M
D. E. Shaw & Co., Inc.
4.3M sh · $154.55M

RATINGS SNAPSHOT

Overall rating: C

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity1
Return On Assets1
Debt To Equity4
Price To Earnings1
Price To Book2
Overall Score2

TRADES BY CONGRESS

HOUSE TRADES
Gilbert Cisneros
Gilbert Cisneros
Purchase
2026-05-13
 Chris Jacobs
Chris Jacobs
Sale (Full)
2022-12-12
 Christopher L. Jacobs
Christopher L. Jacobs
Sale (Full)
2022-12-12

INSIDER TRADES

★
OFFICER: PRESIDENT AND CFO
GUGGENHIME ANDREW
Purchase · 10.0K shares
2026-08-03
★
OFFICER: PRESIDENT AND CFO
GUGGENHIME ANDREW
Sale · 7.0K shares
2026-08-03
★
OFFICER: PRESIDENT AND CFO
GUGGENHIME ANDREW
Sale · 3.0K shares
2026-08-03
★
OFFICER: CHIEF TECHNICAL OPS OFFICER
Dhaliwal Harpreet S.
Purchase · 17.0K shares
2026-08-05

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 2
2 GRADES IN THE LAST 12 MONTHS
BTIG BUY Guggenheim BUY

SECTORS PEERS

PEERPRICE
ARWR$84.91COMPARE
KRYS$351.46COMPARE
CRNX$84.84COMPARE
TGTX$53.93COMPARE
ALKS$47.41COMPARE
PTCT$70.09COMPARE
CRSP$57.72COMPARE